Supernus Pharmaceuticals Total Current Assets 2011-2024 | SUPN

Supernus Pharmaceuticals total current assets from 2011 to 2024. Total current assets can be defined as the sum of all assets that are classified as current because they will provide a benefit within one year.
Supernus Pharmaceuticals Annual Total Current Assets
(Millions of US $)
2023 $493
2022 $734
2021 $602
2020 $630
2019 $473
2018 $493
2017 $228
2016 $151
2015 $106
2014 $109
2013 $97
2012 $91
2011 $49
2010 $
Supernus Pharmaceuticals Quarterly Total Current Assets
(Millions of US $)
2024-09-30 $640
2024-06-30 $591
2024-03-31 $544
2023-12-31 $493
2023-09-30 $449
2023-06-30 $424
2023-03-31 $883
2022-12-31 $734
2022-09-30 $664
2022-06-30 $625
2022-03-31 $569
2021-12-31 $602
2021-09-30 $668
2021-06-30 $639
2021-03-31 $586
2020-12-31 $630
2020-09-30 $552
2020-06-30 $557
2020-03-31 $557
2019-12-31 $473
2019-09-30 $427
2019-06-30 $391
2019-03-31 $420
2018-12-31 $493
2018-09-30 $391
2018-06-30 $285
2018-03-31 $583
2017-12-31 $228
2017-09-30 $191
2017-06-30 $165
2017-03-31 $150
2016-12-31 $151
2016-09-30 $138
2016-06-30 $114
2016-03-31 $94
2015-12-31 $106
2015-09-30 $103
2015-06-30 $106
2015-03-31 $101
2014-12-31 $109
2014-09-30 $103
2014-06-30 $72
2014-03-31 $80
2013-12-31 $97
2013-09-30 $103
2013-06-30 $111
2013-03-31 $76
2012-12-31 $91
2012-09-30 $63
2012-06-30 $78
2012-03-31 $38
2011-12-31 $49
2011-09-30
2011-06-30
2011-03-31
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $1.962B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00